Compare · AIMT vs UROV
AIMT vs UROV
Side-by-side comparison of Aimmune Therapeutics, Inc. (AIMT) and Urovant Sciences Ltd. (UROV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMT and UROV operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Aimmune Therapeutics, Inc.
- Urovant Sciences Ltd.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest AIMT
- SEC Form SC 13G/A filed
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
- ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Latest UROV
- Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
- Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
- Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
- SEC Form 15-12B filed by Urovant Sciences Ltd.
- SEC Form EFFECT filed by Urovant Sciences Ltd.
- SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Ajay Bansal disposed to the issuer $0 worth of Common Shares (140,098 units at $0.00), decreasing direct ownership by 100% to 0 units